HALO News and Press, Halozyme Therapeutics Inc. From 01/04/21

Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO , Jan. 4, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley , president and chief executive offic...

The European Commission ((EC)) has approved Roche's (RHHBY) Phesgo, a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with Halozyme Therapeutics' (HALO) ENHANZE technology, administered by subcutaneous injection for the treatment of patients with early and...

Halozyme Announces Roche Receives European Commission Approval For Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Cancer -...

Halozyme has settled into its role as a royalty cash machine after transitioning away from a drug discovery company, and the immediate future looks very bright. With 5 products currently on the market and 11 trials ongoing using its technology, growing its royalty revenue and profits ...

We’re really intrigued by is Halozyme (HALO), which has a better mousetrap when it comes to drug delivery, asserts Mike Cintolo, editor of Cabot Growth Investor. For further details see: Halozyme- A "Better Mousetrap" in Drug Delivery

Halozyme Therapeutics (HALO) updated FY20 financial guidance reflecting the signing of a global collaboration and license agreement with Horizon Therapeutics.FY20 revenue guidance raised to $265M to $275M (vs. $250 to $260M earlier) growing 35-40% Y/Y growth indicating anticipated revenu...

Halozyme Raises Full Year 2020 Guidance - Raises 2020 Guidance to $265 Million to $275 Million in Revenues, Up from $250 Million to $260 Million, and EPS of $0.90 to $0.95, Up from $0.80 to $0.85 - PR Newswire SAN DIEGO, Nov. 23, 2020 SAN DIEGO , Nov. 23, 2...

Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology - Horizon to use ENHANZE® subcutaneous delivery technology for TEPEZZA® (teprotumumab-trbw) - PR Newswire DUBLIN and SAN DIEGO...

Halozyme To Participate In Fireside Chat For The Piper Sandler 32nd Annual Virtual Healthcare Conference PR Newswire SAN DIEGO, Nov. 18, 2020 SAN DIEGO , Nov. 18, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen...

Halozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For HER2-Positive Breast Cancer - Phesgo® Can be Administered in 5 t...